

Daniel Olive

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7802969/daniel-olive-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

5,347
citations

36
h-index

72
g-index

105
ext. papers

6,568
ext. citations

7.2
avg. IF

5.31
L-index

#	Paper	IF	Citations
89	PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. <i>Cancer Research</i> , 2013 , 73, 128-38	10.1	456
88	Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. <i>Journal of Clinical Investigation</i> , 2011 , 121, 3609-22	15.9	391
87	Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. <i>Blood</i> , 2002 , 99, 3661-7	2.2	380
86	Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human α T-cell subset. <i>Blood</i> , 2012 , 120, 2269-79	2.2	338
85	Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. <i>Blood</i> , 2007 , 109, 323-30	2.2	272
84	Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A β phenotypic and functional characterization. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 139, 335-346.e3	11.5	269
83	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. <i>Journal of Clinical Investigation</i> , 2010 , 120, 157-67	15.9	219
82	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. <i>Blood</i> , 2012 , 120, 4317-23	2.2	217
81	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. <i>Cancer Research</i> , 2015 , 75, 2928-36	10.1	150
80	Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. <i>Journal of Immunology</i> , 2000 , 165, 4397-404	5.3	149
79	ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. <i>Cancer Research</i> , 2012 , 72, 6130-41	10.1	134
78	Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. <i>Oncotarget</i> , 2015 , 6, 14360-73	3.3	118
77	Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. <i>Cancer Research</i> , 2016 , 76, 2153-65	10.1	114
76	The molecular basis for modulation of human α T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. <i>Journal of Biological Chemistry</i> , 2012 , 287, 32780-90	5.4	113
75	Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. <i>Trends in Immunology</i> , 2010 , 31, 391-7	14.4	86
74	RhoB Mediates Phosphoantigen Recognition by α T Cell Receptor. <i>Cell Reports</i> , 2016 , 15, 1973-85	10.6	78
73	Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. <i>European Journal of Immunology</i> , 2004 , 34, 2089-99	6.1	76

72	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. <i>OncImmunology</i> , 2016 , 5, e1064578	7.2	65
71	The co-receptor BTLA negatively regulates human V β V δ T-cell proliferation: a potential way of immune escape for lymphoma cells. <i>Blood</i> , 2013 , 122, 922-31	2.2	65
70	Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018 , 9, 1044	8.4	64
69	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2014 , 5, 122	8.4	62
68	V β V δ TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6. <i>European Journal of Immunology</i> , 2014 , 44, 2571-6	6.1	62
67	Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. <i>OncImmunology</i> , 2019 , 8, e1561120	7.2	59
66	High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. <i>American Journal of Clinical Pathology</i> , 2009 , 132, 589-96	1.9	59
65	The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response. <i>Immunogenetics</i> , 2012 , 64, 781-94	3.2	57
64	Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. <i>European Journal of Immunology</i> , 2011 , 41, 3443-54	6.1	48
63	Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy. <i>Cancer Research</i> , 2016 , 76, 4648-60	10.1	46
62	HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells. <i>Blood</i> , 2012 , 120, 4544-51	2.2	45
61	The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. <i>Current Opinion in Pharmacology</i> , 2012 , 12, 478-85	5.1	45
60	Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γ cells. <i>Journal of Experimental Medicine</i> , 2017 , 214, 1827-1841	16.6	44
59	Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function. <i>Frontiers in Immunology</i> , 2019 , 10, 877	8.4	42
58	Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. <i>Immunology Letters</i> , 2013 , 151, 71-5	4.1	42
57	Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 343-351	6.4	41
56	Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 429-39	4.7	41
55	New Insights Into the Regulation of γ Cells by BTN3A and Other BTN/BTNL in Tumor Immunity. <i>Frontiers in Immunology</i> , 2018 , 9, 1601	8.4	39

54	Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. <i>PLoS ONE</i> , 2009 , 4, e4319	3.7	36
53	Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates V β V α TCR clonotypes and interferes with phosphoantigen activation. <i>European Journal of Immunology</i> , 2017 , 47, 982-992	6.1	32
52	BTN3A molecules considerably improve V β V α T cells-based immunotherapy in acute myeloid leukemia. <i>OncImmunology</i> , 2016 , 5, e1146843	7.2	30
51	BTN3A is a prognosis marker and a promising target for V β V α T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). <i>OncImmunology</i> , 2017 , 7, e1372080	7.2	29
50	Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer. <i>Frontiers in Immunology</i> , 2019 , 10, 1307	8.4	28
49	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2017 , 8, 573	8.4	28
48	The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human V β V α T Cells. <i>Journal of Immunology</i> , 2017 , 198, 4228-4234	5.3	27
47	V β T cell diversity and the receptor interface with tumor cells. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4637-4651	15.9	27
46	Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2016 , 11, e0156063	3.7	27
45	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>OncImmunology</i> , 2020 , 9, 1832348	7.2	27
44	Butyrophilin 3A/CD277-Dependent Activation of Human T β Cells: Accessory Cell Capacity of Distinct Leukocyte Populations. <i>Journal of Immunology</i> , 2016 , 197, 3059-3068	5.3	26
43	Hepatitis C virus fails to activate NF- κ B signaling in plasmacytoid dendritic cells. <i>Journal of Virology</i> , 2012 , 86, 1090-6	6.6	26
42	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. <i>OncImmunology</i> , 2017 , 6, e1307491	7.2	24
41	Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors. <i>Frontiers in Immunology</i> , 2018 , 9, 797	8.4	24
40	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. <i>Oncotarget</i> , 2017 , 8, 49548-49563	3.3	23
39	NKG2C memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147. <i>Clinical and Translational Immunology</i> , 2017 , 6, e150	6.8	22
38	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. <i>Frontiers in Immunology</i> , 2016 , 7, 94	8.4	22
37	Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. <i>PLoS ONE</i> , 2017 , 12, e0179201	3.7	21

36	Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRV β + Γ lymphocytes. <i>Immunology Letters</i> , 2014 , 161, 133-7	4.1	21
35	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. <i>Cancer Immunology Research</i> , 2019 , 7, 150-161	12.5	21
34	The SH3 domain of Tec kinase is essential for its targeting to activated CD28 costimulatory molecule. <i>European Journal of Immunology</i> , 2004 , 34, 1972-80	6.1	19
33	Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. <i>Human Pathology</i> , 2017 , 64, 128-136	3.7	18
32	Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies. <i>Frontiers in Immunology</i> , 2019 , 10, 1876	8.4	18
31	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. <i>Human Pathology</i> , 2014 , 45, 2085-93	3.7	18
30	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2015 , 6, 564	8.4	18
29	The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 364	8.4	16
28	Ligation of the BT3 molecules, members of the B7 family, enhance the proinflammatory responses of human monocytes and monocyte-derived dendritic cells. <i>Molecular Immunology</i> , 2010 , 48, 109-18	4.3	16
27	Natural killer cell-triggering receptors in patients with acute leukaemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1683-9	1.9	16
26	Evolutionary and polymorphism analyses reveal the central role of BTN3A2 in the concerted evolution of the BTN3 gene family. <i>Immunogenetics</i> , 2017 , 69, 379-390	3.2	14
25	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. <i>Frontiers in Immunology</i> , 2018 , 9, 977	8.4	14
24	Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model. <i>Frontiers in Immunology</i> , 2017 , 8, 756	8.4	14
23	Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis		14
22	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. <i>Oncolmmunology</i> , 2019 , 8, 1615818	7.2	13
21	A Mature NK Profile at the Time of HIV Primary Infection Is Associated with an Early Response to cART. <i>Frontiers in Immunology</i> , 2017 , 8, 54	8.4	13
20	NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27. <i>Oncotarget</i> , 2017 , 8, 35088-35102	3.3	13
19	Photoactivated cyclization of aryl-containing enediynes coated gold nanoparticles: enhancement of the DNA cleavage ability of enediynes. <i>Colloids and Surfaces B: Biointerfaces</i> , 2013 , 112, 513-20	6	11

18	Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA. <i>European Journal of Medicinal Chemistry</i> , 2018 , 148, 306-313	6.8	10
17	HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma. <i>Onc Immunology</i> , 2019 , 8, e1665976	7.2	10
16	Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. <i>Journal of Leukocyte Biology</i> , 2021 , 109, 1071-1088	6.5	10
15	BTN2A1, an immune checkpoint targeting V β V β T cell cytotoxicity against malignant cells. <i>Cell Reports</i> , 2021 , 36, 109359	10.6	8
14	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	7
13	Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V β V β T cell-mediated antitumor immune response. <i>Science Translational Medicine</i> , 2021 , 13, eabj0835	17.5	6
12	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020 , 4, 5203-5214	7.8	6
11	Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. <i>Biomedicines</i> , 2021 , 9,	4.8	6
10	T β Cells in Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1273, 91-104	3.6	5
9	An X-ray Vision for Phosphoantigen Recognition. <i>Immunity</i> , 2019 , 50, 1026-1028	32.3	4
8	Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021 , 12, 670827	8.4	3
7	Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.. <i>Frontiers in Immunology</i> , 2021 , 12, 730970	8.4	2
6	Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma. <i>Cancers</i> , 2021 , 13,	6.6	2
5	Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. <i>Blood Advances</i> , 2021 , 5, 1816-1829	7.8	2
4	Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice. <i>Cancers</i> , 2021 , 13,	6.6	2
3	A Tribute to Alessandro Moretta (1953-2018). Living Without Alessandro. <i>Frontiers in Immunology</i> , 2018 , 9,	8.4	1
2	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. <i>Cancers</i> , 2021 , 13,	6.6	1
1	Phosphoantigen-stimulated T β cells suppress natural killer cell-responses to missing-self.. <i>Cancer Immunology Research</i> , 2022 ,	12.5	1

